Traditional Chinese medicine MiR2911 and application thereof in preparation of medicine for treating / relieving intestinal microbiological disorder diseases

MiR2911 small RNA extracted from honeysuckle regulates intestinal flora and combined with mesalazine to combine it with the problem of poor IBD treatment effect and imbalance in intestinal flora, achieving safe and efficient intestinal inflammation treatment and improvement of flora balance .

CN118910041APending Publication Date: 2024-11-08NANJING UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202310502605.X
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2023-05-06
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

Inflammatory bowel disease (IBD) is not effective. Existing drugs such as nonsteroidal anti-inflammatory drugs and corticosteroids have side effects, and imbalance in intestinal flora has potential impact on the disease. Honeysuckle Decoction has unclear mechanism for improving IBD.

Method used

The MiR2911 small RNA sequence in honeysuckle was extracted, and drugs were prepared for the treatment of relieving intestinal microbial disorders were prepared by regulating the composition of intestinal microbial disorders, combined with mesalazine to enhance the therapeutic effect.

Benefits of technology

Significantly improve DSS-induced colitis, reduce IL-1β levels, increase IL-10 levels, improve intestinal flora balance, reduce harmful bacteria, increase probiotics, reduce side effects, and improve treatment effect.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118910041A_ABST
    Figure CN118910041A_ABST
Patent Text Reader

Abstract

The invention discloses an RNA sequence 1 as shown in SEQ ID No.1 in a sequence table or a sequence which has more than 90% of homology and has the same function, and discloses application of the RNA sequence 1. Compared with the prior art, the traditional Chinese medicine MiR2911 and the application of the MiR2911 in preparation of the medicine for treating / relieving intestinal microbiological disorder diseases have the advantages that the small RNA nucleic acid medicine MIR2911 in the honeysuckle flower extract can be used for treating colitis and treating diseases caused by intestinal flora disorder, and the application of the MiR2911 in preparation of the medicine for treating / relieving the intestinal microbiological disorder diseases in preparation of the medicine for treating / relieving the intestinal microbiological disorder diseases in preparation of the medicine for treating / relieving the intestinal microbiological disorder diseases is provided. Compared with non-steroidal anti-inflammatory drugs and corticosteroid drugs, the pharmaceutical composition has the advantages of higher safety and no toxic side effects.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of biotechnology, and in particular to MiR2911 of traditional Chinese medicine and application thereof in preparing medicines for treating / alleviating intestinal microbial disorder diseases. Technical Background

[0002] Inflammatory bowel disease (IBD) is an idiopathic, chronic intestinal inflammatory disease that affects the ileum, rectum, and colon. The condition is prone to recurrence and is not cured, often causing pain to patients and causing a lot of mental and daily distress. The treatment of IBD is far from optimal and currently includes nonsteroidal anti-inflammatory drugs and corticosteroids. However, nonsteroidal anti-inflammatory drugs, such as aminosalicylate, can only have a certain therapeutic effect; while steroid drugs can relieve certain symptoms, they have potential side effects, such as allergies, adrenal suppression, and lymphoma.

[0003] Honeysuckle is a traditional Chinese herbal medicine. Ancient prescriptions show that honeysuckle has a certain therapeutic effect on inflammatory bowel disease. A single honeysuckle soup has a preventive and ameliorative effect on the DSS-induced inflammatory bowel disease mouse model. However, the specific mechanism of the improvement effect of honeysuckle soup is not clear. microRNAs (MIRNA) are a class of single-stranded non-coding small RNAs with a length of about 19-23 nt. MIRNAs in plants can be ingested by animals through diet, and regulate the expression of endogenous genes in animals to play biological functions.

[0004] Intestinal flora imbalance is common in the intestines of IBD patients, and the intestinal microbial population fluctuations of IBD patients (including ulcerative colitis UC and Crohn's disease CD) are greater than those of healthy controls. The abundance of beneficial bacteria is greatly reduced, while the number of harmful bacteria increases, which has potential implications for the occurrence and development of the disease. Summary of the invention

[0005] In view of the above-mentioned technical limitations, the present invention proposes MiR2911 of traditional Chinese medicine and its application in the preparation of drugs for treating / alleviating intestinal microbial disorder diseases. MIR2911 is the most abundantly expressed small RNA in honeysuckle, and it alleviates DSS-induced colitis by regulating the community composition of intestinal flora, overcoming the deficiencies and defects mentioned in the background technology.

[0006] To achieve the above object, the present invention adopts the following technical solutions:

[0007] The invention point of the present invention is to provide an RNA sequence, wherein the RNA sequence is RNA sequence 1 shown in SEQ ID No. 1 in the sequence table or a sequence having more than 90% homology thereto and having the same function.

[0008] RNA sequence 1 is precursor sequence>peu-MIR2911.

[0009] SEQ ID No.1 is specifically:

[0010] UCCCAGUCCCGAACCCGUCGGCUGUCCGGUGGACUGCUCGAGCUGCUCCCGCGGCAAGAGCGGGUCGUCGCGCCGGCCGGGGGACGGGCUGGGA.

[0011] The second inventive point of the present invention is to provide an RNA sequence, wherein the RNA sequence is RNA sequence 2 shown in SEQ ID No. 2 in the sequence table or a sequence having more than 90% homology thereto and having the same function, and the RNA sequence 1 is a precursor sequence of the RNA sequence 2.

[0012] RNA sequence 2 and its homologous sequence are MIR2911 sequences.

[0013] SEQ ID No.2 is specifically:

[0014] GGCCGGGGGACGGACUGGGA.

[0015] The homologous sequence SEQ ID No.3 with more than 90% homology is specifically:

[0016] CGGCCGGGGGACGGGCUGGG.

[0017] Optionally, among the above-mentioned RNA sequences, the RNA sequence 2 and its homologous sequence are MIR2911, which are derived from the RNA extract of the traditional Chinese medicine honeysuckle.

[0018] The specific preparation method of honeysuckle RNA extract is as follows:

[0019] The universal plant microRNA extraction kit was used for extraction. The specific steps are as follows:

[0020] 1) Honeysuckle: Grind with liquid nitrogen, take 100 mg of honeysuckle powder and place it in a 1.5 mL RNase-free EP tube; Honeysuckle decoction: Take 100 μL of the concentrated decoction and place it in a 1.5 mL RNase-free EP tube;

[0021] 2) Add 1 mL of lysis solution PL to the EP tube, invert and mix, and place in a 65°C metal bath for 10 min (invert and mix 3-5 times during this period to ensure complete lysis of the nuclear protein);

[0022] 3) Centrifuge at 12,000 × g for 5 min at room temperature and transfer the supernatant to a new 2 mL RNase-free EP tube;

[0023] 4) Add an equal volume of pre-cooled isopropanol, mix by inversion, and centrifuge at 12,000×g for 5 min at 4°C;

[0024] 5) Remove the supernatant, dry for 2 minutes, and add 100 μL DEPC water to dissolve to obtain the RNA crude extract; DEPC is diethyl pyrocarbonate;

[0025] 6) Add 900 μL of lysis buffer MRL, mix thoroughly, add 200 μL of chloroform, invert several times, vortex to mix, and place on ice for 5 min;

[0026] 7) Centrifuge at 4°C, 12,000×g for 10 min. After centrifugation, the sample is separated into two layers (the lower organic phase is chloroform, the upper inorganic phase is water, and the RNA is dissolved in the upper aqueous phase). Carefully pipette the upper aqueous phase into a new 2 mL RNase-free EP tube and measure the volume;

[0027] 8) Add 0.6 times the volume of 70% ethanol, mix by inverting, transfer the mixed solution to the adsorption column RA, centrifuge at 4°C, 12,000×g for 2 min, and collect the filtrate after centrifugation;

[0028] 9) Transfer the collected filtrate to a new 2 mL RNase-free EP tube, add 2 / 3 volume of anhydrous ethanol, invert and mix, transfer the mixed solution to the adsorption column RB, centrifuge at 4°C, 12,000×g for 1 min, and discard the filtrate;

[0029] 10) Add 700 μL of rinse solution PW, centrifuge at 4°C, 12,000 × g for 1 min, discard the filtrate, then add 500 μL of rinse solution PW, centrifuge at 4°C, 12,000 × g for 1 min, discard the filtrate;

[0030] 11) Place the adsorption column RB in an empty recovery tube and centrifuge at 12,000×g for 2 min at 4°C. Take out the adsorption column RB and place it in a new 1.5mL RNase-free EP tube. Add 30-50μL of DEPC water (preheated at 65°C). After standing at room temperature for 2 min, centrifuge at 12,000×g for 2 min. Collect the RNA filtrate and store it at -80°C for later use.

[0031] The third inventive aspect of the present invention is to provide the use of the above-mentioned RNA sequence in the preparation of a pharmaceutical product for treating / alleviating colitis.

[0032] The fourth inventive aspect of the present invention is to provide the use of the above-mentioned RNA sequence in the preparation of a pharmaceutical product for treating / alleviating enteritis.

[0033] The fifth inventive point of the present invention is to provide the use of the above-mentioned RNA sequence in the preparation of a pharmaceutical product for treating / alleviating diseases related to intestinal flora disorders.

[0034] The sixth invention point of the present invention is to provide the use of the above-mentioned RNA sequence in the preparation of a pharmaceutical product for treating / alleviating intestinal pathogenic bacteria-related diseases, wherein the pathogenic bacteria are Escherichia pathogenic bacteria and / or Shigella pathogenic bacteria.

[0035] The seventh invention of the present invention is to provide the use of the above RNA sequence in the preparation of a pharmaceutical product for treating / alleviating intestinal probiotic-related diseases, wherein the probiotics are Akkermansia and / or lactic acid bacteria.

[0036] In the above application, the effective dosage of this RNA sequence (MIR2911) is 30 μg (RNA) / Kg (body weight).

[0037] The present invention also provides a combined drug preparation that can be used in combination with the above RNA sequence, and the combined drug preparation can further play a better therapeutic effect on intestinal diseases.

[0038] The drug preparation that can be used in combination is: mesalazine.

[0039] Compared with the prior art, the present invention has the following advantages: the traditional Chinese medicine MiR2911 provided by the present invention and its use in the preparation of drugs for treating / alleviating intestinal microbial disorder diseases, discloses that the small RNA nucleic acid drug MIR2911 in honeysuckle extract can be used to treat colitis and treat diseases caused by intestinal flora disorders. Compared with non-steroidal anti-inflammatory drugs and corticosteroids, it is safer and has no toxic side effects. BRIEF DESCRIPTION OF THE DRAWINGS

[0040] Figure 1 Shown is a schematic diagram of the MIR2911 administration to treat the DSS-induced colitis model in C57BL / 6J mice.

[0041] Figure 2 MIR2911 administration was shown to treat DSS-induced colitis in C57BL / 6J mice;

[0042] Figure 2 a is a statistical chart showing the effect of MIR2911 administration on body weight percentage.

[0043] Figure 2 b is a representative diagram of the effect of MIR2911 administration on colon length,

[0044] Figure 2 c is a statistical graph showing the effect of MIR2911 administration on colon length.

[0045] Figure 2 d is a representative histological image of HE sections after administration of MIR2911.

[0046] Figure 2 e is the statistical chart of the histological section scoring results after MIR2911 administration,

[0047] Figure 2 f is the statistical chart of the expression level of inflammatory factor IL-1β after administration of MIR2911,

[0048] Figure 2 g is a statistical graph of the expression level of the inflammatory factor IL-10 after administration of MIR2911.

[0049] Figure 3 The graph shows the abundance of species in 16s rDNA sequencing. The colitis treatment group was given treatment at the same time as the colitis modeling, and the normal group MIR2911 treatment group was not given colitis modeling, but was given 2911 by gavage.

[0050] Figure 3 a is the species abundance diagram at the phylum classification level of the colitis treatment group,

[0051] Figure 3 b is the species abundance diagram at the genus classification level of the colitis treatment group,

[0052] Figure 3 c is the species abundance diagram at the phylum classification level in the normal group and the MIR2911 treatment group.

[0053] Figure 3 d is the species abundance diagram at the genus classification level in the normal group and the MIR2911-treated group. DETAILED DESCRIPTION

[0054] In order to make the purpose, technical solution and advantages of the present invention more clear, the present invention is further described in detail below. However, it should be understood that the description herein is only used to explain the present invention and is not used to limit the scope of the present invention.

[0055] Unless otherwise defined, all technical terms and scientific terms used herein have the same meaning as those generally understood by those skilled in the art of the present invention, and the terms used in the specification of the present invention are only for the purpose of describing specific embodiments and are not intended to limit the present invention. The reagents and instruments used herein are all commercially available, and the characterization means involved can refer to the relevant descriptions in the prior art, which will not be repeated herein.

[0056] In order to further understand the present invention, the present invention is further described in detail below in conjunction with the best embodiment. Example 1

[0057] An RNA sequence is RNA sequence 1 shown as SEQ ID No. 1 in the sequence table or a sequence having more than 90% homology thereto and having the same function.

[0058] RNA sequence 1 is precursor sequence>peu-MIR2911.

[0059] SEQ ID No.1 is specifically:

[0060] UCCCAGUCCCGAACCCGUCGGCUGUCCGGUGGACUGCUCGAGCUGCUCCCGCGGCAAGAGCGGGUCGUCGCGCCGGCCGGGGGACGGGCUGGGA.

[0061] An RNA sequence is RNA sequence 2 shown as SEQ ID No. 2 in the sequence table or a sequence having more than 90% homology thereto and having the same function, and RNA sequence 1 is a precursor sequence of RNA sequence 2.

[0062] RNA sequence 2 and its homologous sequence are MIR2911 sequences.

[0063] SEQ ID No.2 is specifically:

[0064] GGCCGGGGGACGGACUGGGA.

[0065] The homologous sequence SEQ ID No.3 with more than 90% homology is specifically:

[0066] CGGCCGGGGGACGGGCUGGG.

[0067] RNA sequence 2 and its homologous sequence MIR2911 are derived from the RNA extract of the traditional Chinese medicine honeysuckle.

[0068] The specific preparation method of honeysuckle RNA extract is as follows:

[0069] The universal plant microRNA extraction kit was used for extraction. The specific steps are as follows:

[0070] 1) Honeysuckle: Grind with liquid nitrogen, take 100 mg of honeysuckle powder and place it in a 1.5 mL RNase-free EP tube; Honeysuckle decoction: Take 100 μL of the concentrated decoction and place it in a 1.5 mL RNase-free EP tube;

[0071] 2) Add 1 mL of lysis solution PL to the EP tube, invert and mix, and place in a 65°C metal bath for 10 min (invert and mix 3-5 times during this period to ensure complete lysis of the nuclear protein);

[0072] 3) Centrifuge at 12,000 × g for 5 min at room temperature and transfer the supernatant to a new 2 mL RNase-free EP tube;

[0073] 4) Add an equal volume of pre-cooled isopropanol, mix by inversion, and centrifuge at 12,000×g for 5 min at 4°C;

[0074] 5) Remove the supernatant, dry for 2 minutes, and add 100 μL DEPC water to dissolve to obtain the RNA crude extract; DEPC is diethyl pyrocarbonate;

[0075] 6) Add 900 μL of lysis buffer MRL, mix thoroughly, add 200 μL of chloroform, invert several times, vortex to mix, and place on ice for 5 min;

[0076] 7) Centrifuge at 4°C, 12,000×g for 10 min. After centrifugation, the sample is separated into two layers (the lower organic phase is chloroform, the upper inorganic phase is water, and the RNA is dissolved in the upper aqueous phase). Carefully pipette the upper aqueous phase into a new 2 mL RNase-free EP tube and measure the volume;

[0077] 8) Add 0.6 times the volume of 70% ethanol, mix by inverting, transfer the mixed solution to the adsorption column RA, centrifuge at 4°C, 12,000×g for 2 min, and collect the filtrate after centrifugation;

[0078] 9) Transfer the collected filtrate to a new 2 mL RNase-free EP tube, add 2 / 3 volume of anhydrous ethanol, invert and mix, transfer the mixed solution to the adsorption column RB, centrifuge at 4°C, 12,000×g for 1 min, and discard the filtrate;

[0079] 10) Add 700 μL of rinse solution PW, centrifuge at 4°C, 12,000 × g for 1 min, discard the filtrate, then add 500 μL of rinse solution PW, centrifuge at 4°C, 12,000 × g for 1 min, discard the filtrate;

[0080] 11) Place the adsorption column RB in an empty recovery tube and centrifuge at 12,000×g for 2 min at 4°C. Take out the adsorption column RB and place it in a new 1.5mL RNase-free EP tube. Add 30-50μL of DEPC water (preheated at 65°C). After standing at room temperature for 2 min, centrifuge at 12,000×g for 2 min. Collect the RNA filtrate and store it at -80°C for later use.

[0081] RNA-seq (MIR2911) has a variety of applications, including:

[0082] Application in the preparation of a pharmaceutical product for treating / alleviating colitis;

[0083] Application in the preparation of a pharmaceutical product for treating / alleviating enteritis;

[0084] Application in the preparation of pharmaceutical products for treating / alleviating diseases related to intestinal flora disorders;

[0085] Application in the preparation of a pharmaceutical product for treating / alleviating intestinal pathogenic bacteria-related diseases, wherein the pathogenic bacteria are Escherichia pathogenic bacteria and / or Shigella pathogenic bacteria;

[0086] Application in the preparation of a pharmaceutical product for treating / alleviating intestinal probiotic-related diseases, wherein the probiotics are Akkermansia and / or lactic acid bacteria.

[0087] In the above application, the effective dosage of this RNA sequence (MIR2911) is 30 μg (RNA) / Kg (body weight).

[0088] The combined drug preparation that can be used in combination with the above-mentioned RNA sequence is mesalazine, and the combined drug use can further play a better therapeutic effect on intestinal diseases. Example 2

[0089] MIR2911 has high abundance and stability during the boiling preparation process.

[0090] In this example, dextran sulphate sodium (DSS) was used to induce a colitis mouse model. Figure 1 As shown, it was used to verify the therapeutic effect of MIR2911 on DSS-induced colitis.

[0091] The model building process is as follows:

[0092] 1) Day 0-Day 7: Weigh and mark each group of C57BL / 6 mice, drink 2.5% DSS aqueous solution every day, and observe the mental state, diarrhea, bloody stool and body weight of the mice every day;

[0093] 2) Day 7-Day 9: Give the mice to be modeled fresh drinking water without DSS;

[0094] 3) Follow-up analysis on Day 9.

[0095] 1 nmol of synthetic MIR2911 or negative control RNA (NC) was administered by gavage. Figure 2 As shown in Figure 2, the weight loss of mice after DSS modeling ( Figure 2 a) and shortened colon length ( Figure 2 b. Figure 2 c), the body weight of mice in the MIR2911 treatment group was significantly increased ( Figure 2 a), the length of the colon also increases ( Figure 2 b. Figure 2 c). Histological analysis showed that oral administration of 1 nmol MIR2911 significantly improved epithelial cell and crypt damage, mucosal and submucosal damage, lamina propria edema, intestinal wall structural lesions, and immune cell infiltration induced by DSS treatment ( Figure 2 d. Figure 2 e). The detection of inflammatory factors also showed that MIR2911 inhibited inflammation by reducing IL-1β levels and increasing IL-10 levels ( Figure 2 f. Figure 2 g). Example 3

[0096] In order to verify the effect of MIR2911 in treating / alleviating intestinal flora disorders, reducing the level of intestinal pathogens, and increasing the level of intestinal probiotics, 16s rDNA sequencing was performed on the MIR2911 treatment group in this example. The MIR2911 targeted in this example is the sequence shown in RNA sequence 2 (i.e., SEQ ID No. 2), but because the sequence shown in its homologous sequence (i.e., SEQ ID No. 3) is derived from the same precursor, and the two actually only differ in 2 bases, the functional effects of this RNA sequence 2 must also be possessed by its homologous sequence.

[0097] Through 16s rDNA sequencing, it was found that Figure 3 As shown, the MIR2911 treatment group can significantly increase the ratio of Bacteroidota to Proteobacteria at the phylum level (the reduced ratio of Bacteroidota to Proteobacteria is an indicator of bacterial disorder in the intestinal flora during colitis), reduce the abundance of various harmful bacteria such as Escherichia-Shigella at the genus level, and increase the abundance of probiotics such as Akkermansia and Lactobacillus in the absence of pathological damage caused by colitis. Example 4

[0098] In this embodiment, a combined drug preparation that can be used in combination with the above-mentioned RNA sequence is provided, and the combined drug preparation can further play a better therapeutic effect on intestinal diseases.

[0099] The drug preparation that can be used in combination is mesalazine.

[0100] When used in combination, the effective dosage of RNA sequence (MIR2911) is 30 μg (RNA) / Kg (body weight), and the effective dosage of mesalazine is 60 mg / kg.

[0101] The same model as in Example 2 was used to verify the therapeutic effects of MIR2911 alone and MIR2911 + mesalazine on colitis. The verification results are shown in Table 1 below.

[0102] Table 1 shows the effects of MIR2911 alone and MIR2911 + mesalazine combined.

[0103] Table 1

[0104] From the test results in Table 1, it can be seen that, based on the verification that MIR2911 alone has excellent effects in the treatment of intestinal diseases, the combination of MIR2911 and mesalazine, using the same mouse model, can verify that the combination can achieve a better therapeutic effect on intestinal inflammatory diseases than using MIR2911 alone.

[0105] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. Any modification, equivalent substitution or improvement made within the spirit and principle of the present invention should be included in the protection scope of the present invention.

Claims

1. An RNA, characterized in that The RNA sequence is RNA sequence 1 shown in SEQ ID No. 1 in the sequence list or a sequence having more than 90% homology thereto and having the same function.

2. An RNA sequence, characterized in that The RNA sequence is RNA sequence 2 shown in SEQ ID No. 2 in the sequence list or a sequence having more than 90% homology thereto and having the same function, and the RNA sequence 1 described in claim 1 is a precursor sequence of the RNA sequence 2.

3. The RNA sequence according to claim 1 or 2, characterized in that The RNA sequence 2 and its homologous sequence are MIR2911, which are derived from the RNA extract of the traditional Chinese medicine honeysuckle.

4. Use of the RNA sequence according to any one of claims 1 to 3 in the preparation of a pharmaceutical product for treating / alleviating colitis.

5. Use of the RNA sequence according to any one of claims 1 to 3 in the preparation of a pharmaceutical product for treating / alleviating enteritis.

6. Use of the RNA sequence according to any one of claims 1 to 3 in the preparation of a pharmaceutical product for treating / alleviating diseases related to intestinal flora disorders.

7. Use of the RNA sequence according to any one of claims 1 to 3 in the preparation of a pharmaceutical product for treating / alleviating intestinal pathogenic bacteria-related diseases, characterized in that: The pathogenic bacteria are Escherichia pathogenic bacteria and / or Shigella pathogenic bacteria.

8. Use of the RNA sequence according to any one of claims 1 to 3 in the preparation of a pharmaceutical product for treating / alleviating intestinal probiotic-related diseases, characterized in that: The probiotics are Akkermansia and / or lactic acid bacteria.

9. Use of the RNA sequence according to any one of claims 1 to 3 in the preparation of a pharmaceutical product for treating / alleviating colitis, enteritis, intestinal flora disorder-related diseases, intestinal pathogenic bacteria-related diseases, and intestinal probiotics-related diseases, characterized in that: The pharmaceutical product also includes drugs / preparations used in combination with the RNA sequence.

10. The use according to claim 9, characterized in that: The drug / preparation used in combination with the RNA sequence is mesalazine.